Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MUST WATCH the amazing LXGTF video: https://vimeo.com/183611304
NEW HERE? Start your dd from LXGTF website: https://lexingtonbiosciences.com/
Hello Italian, we are early worriors lol
Good morning everybody!
interesting...
LXGTF is a stable stronghold
a little down red, no worries
Can we see it back to green today?
LXGTF Press Release from October 23, 2017: LXGTF receives delivery of first HeartSentry units from the manufacturer.: http://www.otcmarkets.com/stock/LXGTF/news/Lexington-Biosciences-Receives-HeartSentry-Trial-Units?id=173009&b=y
The FACTS ARE: Undiagnosed Cardiovascular Disease Is a Killer
• 1 in 3 deaths annually are caused by heart disease
and stroke.
• 1.5 million people suffer heart attacks annually in
the U.S.
• Nearly 1/3 of the deaths could be prevented
through proactive changes in lifestyle habits.
• Often the FIRST SYMPTOM of coronary artery
disease is a heart attack.
WHY LXGTF is better? Knowing the core health of the cardiovascular system is critical to
preventing future heart attacks and strokes
• Monitoring cardiovascular health changes over time is key to prevention via
lifestyle modification, physician care and ongoing monitoring.
• Traditional measures of blood pressure and cholesterol measurements are only
partial indicators of cardiovascular health.
LXGTF Corporate Profile: https://lexingtonbiosciences.com/investors/corporate-profile/
LXGTF Corporate Profile: https://lexingtonbiosciences.com/investors/corporate-profile/
LXGTF Corporate Presentation: https://lexingtonbiosciences.com/wp-content/uploads/2017/10/Lexington-Website-Presentation.pdf
NEW TO LXGTF? NEED SOME READING MATERIAL??
START DD HERE:
https://lexingtonbiosciences.com/wp-content/uploads/2017/10/Lexington-Website-Presentation.pdf
NEW TO LXGTF? NEED SOME READING MATERIAL??
START DD HERE:
https://lexingtonbiosciences.com/wp-content/uploads/2017/10/Lexington-Website-Presentation.pdf
Adama Technologies Corp Announces Details Regarding New Digital Currency Partnership
LAS VEGAS, NV / ACCESSWIRE / December 14, 2017 / Adama Technologies Corp. (OTC PINK: ADAC) released additional details today regarding the launch of their new digital currency called CryX. As previously announced, CryX will be traded and exchanged within a cyber store owned, operated and managed by Adama Technologies Corp. Additionally, Adama Technologies announced a partnership with a new crypto currency exchange site called Bit Trader Live (www.BitTraderLive.com), in which CryX would be processed and exchanged for users wishing to hold or exchange the token. Today, the company provided additional context on the timing and features that will be offered within the exchange as well as the token itself.
GO ADAC!
With the news of additional product offerings, Adama plans for the CryX marketplace to focus on mid to high end consumer products that can all be bought and sold utilizing the CryX token. Mr. Sills continued, "We are envisioning a customer experience where anyone, anywhere, and at any time, can log into their app, trade and exchange tokens, shop for their favorite products, move tokens or cash between wallets and transfer money to their connected card, bank, and utilize other online wallet accounts. We want to allow crypto transactions to be easy, accessible and secure to all of our users and customers. Our vision is to bring this great technology, flexibility and freedom into a mainstream experience that is just one click or one download away."
shorter week, a little deep
lets see the power hour here
The Company also stated that recent developments in the crypto retail space are very encouraging as they pointed to the recent ICO and news releases issued by Overstock.com (NASDAQ:OSTK). Overstock.com, through their subsidiary, tZERO, has launched their own Security Token Sale and are considering benefits of token holders including the possibility of discounted merchandise and even free membership in Overstock’s rewards program. Overstock CEO Patrick Byrne said: “Overstock is proud to be the market-leading enterprise embracing the cryptorevolution. Recognizing the blockchain technology-driven transformation and disruption already underway across numerous industries, Overstock today opens the tZERO ICO.”
some recovery needed here, small valume today
See Why LXGTF's Technology Could Disrupt an Industry Worth Billions Here
Company President, Eric Willis, stated, "We are delighted to take delivery of these first HeartSentry human-use units from our manufacturer. The design and production team have worked for nine months to perfect the HeartSentry technology and device design, and we have achieved a significant milestone by moving the HeartSentry out of the lab and into a hand-held mobile unit ready for clinical trials. We look forward to being able to commence study enrollment in our upcoming HeartSentry clinical study in order to gather the foundational dataset aimed at supporting FDA clearance."
Lexington's President Eric Willis comments, "As recently announced, we are moving ahead quickly towards the commencement of our HeartSentry pilot clinical research study designed to build the foundational dataset ultimately aimed at supporting FDA clearance. As we plan for market entry, we know that a key element to commercial success will come from fielding a product that meets the threshold for medical insurance coverage. Regulatory approval rarely guarantees payment coverage for new devices, so we are undertaking what we believe is the prudent strategy of beginning that process today. We are delighted to have the opportunity to work with the Navigant team and feel certain the advice and direction we receive will prove invaluable towards providing HeartSentry the best strategy for market introduction."
Navigant Consulting is a specialized professional services firm based in Chicago, Illinois. The company has nearly 50 offices across the United States, Canada, Europe, Middle East and Asia. Navigant recently acquired Quorum Consulting, a San Francisco based specialist service provider with extensive experience in the field of medical device reimbursement and health economics. Services include a proven ability to define strategic business opportunities and of influencing global coverage and payment policies. For more information, visit: http://www.navigant.com .
The Cryx marketplace will feature mid to high end consumer products that can all be bought and sold utilizing the Cryx token. Mr. Sills continued, "We are envisioning a product where a customer can log into their app, trade and exchange tokens, shop for their favorite products, move tokens between wallets and transfer money to their connected card, bank or other online wallet accounts. Our team of designers and developers have really caught the vision of what we are trying to build and what we will accomplish in blending and marrying the cryptocurrency and online retail sectors. We will be providing customers an entirely unique online retail experience and offer them flexibility and freedom in how they choose to pay for their purchases. Our partnership with BitTraderLive is a huge leap forward in allowing us to accomplish and achieve the vision we have outlined for this exciting new opportunity."
The Company also stated that recent developments in the crypto retail space are very encouraging as they pointed to the recent ICO and news releases issued by Overstock.com (NASDAQ:OSTK). Overstock.com, through their subsidiary, tZERO, has launched their own Security Token Sale and are considering benefits of token holders including the possibility of discounted merchandise and even free membership in Overstock's rewards program. Overstock CEO Patrick Byrne said: "Overstock is proud to be the market-leading enterprise embracing the cryptorevolution. Recognizing the blockchain technology-driven transformation and disruption already underway across numerous industries, Overstock today opens the tZERO ICO."
this Dr. Maltz on the management team isawesome! : https://lexingtonbiosciences.com/company/management/
LXGTF Article by Jonathan Maltz, "What is Endothelial Function..." : https://lexingtonbiosciences.com/news/endothelial-function-important-health/
Green early opening, love it :)
GOOD ARTICLE RECENTLY RELEASED
https://insiderfinancial.com/lexington-bioscien-otcmktslxgtf-venturing-into-fortune-500-territory
"Breakthrough technology" is a real understatement. In LXGTF HeartSentry you have a simple, affordable, portable device that requires no expert training to use and yet by measuring endothelial function it can knock the wind out of the diseases that cause 25% of ALL deaths in the modern world (heart disease and stroke)Its only competition area devices that cost up to six figures, can fill a small room and require medical training to operate.
LXGTF engages Diablo research for next step in FDA clearance..
https://finance.yahoo.com/news/lexington-biosciences-engages-clinical-research-140000876.html
CHECK THIS! Lexington’s President Eric Willis comments, “After nine months of concerted effort by our design and production team, the arrival of our first human-use HeartSentry devices allows us to accelerate our plans to move ahead with our pilot study. Diablo Clinical Research is a proven and respected establishment with the capability to launch our research program efficiently and cost-effectively. They have been extremely helpful in the determination process which has led to today’s announcement. We are excited to begin this next step of our development phase, and look forward to sharing quantifiable results in the near future.
http://techstockinsider.com/lexington-biosciences-lxgtf-lnb-engages-clinical-research-organization/?utm_medium=Social&utm_source=TSI_Social_Link&utm_campaign=TSI_Social_1130
Good morning Italian :)
How it Works??
The proprietary HeartSentry™ inflatable cuff utilizes
specialized algorithms to interpret changes in the volume
of blood in the arm. In a relaxed, dilated artery, the
volume change over the cardiac cycle is much greater
than baseline levels, typically by more than 80% in
healthy subjects.
The fully automated device is compact and inexpensive
enough for commercial use in the home care market and
primary care physician offices. Its integrated Bluetooth
technology can communicate with nearby smart
applications which can act as a portal to cloud-based
technologies enabling advanced ongoing monitoring
opportunities between patient and clinical care providers.
There is a potential for generated data to be valuable to
bioinformatics providers. Integration with additional data
streams allows further predictive ability for assessing
cardiovascular disease progression.
HeartSentry™ is a combination device that measures
BOTH blood pressure and endothelial function. This
ADDED FEATURE increases the value and interest in
purchasing a blood pressure and endothelial function
monitoring device, and is designed to deliver a more
accurate picture of cardiovascular health.
Initially targeted at the clinic based professional
market, the product ultimately will be marketed direct
to consumers.
OPPORTUNITY: HIGH GROWTH SELF-MONITORING SECTOR
By 2020, $2.6 billion Global monitoring instruments market
will increasingly shift to the high-growth home segment.
HeartSentry™ has been developed to measure the
function of the endothelium, the cells that line all
arteries and are critical to the prevention of
atherosclerosis, heart attacks and stroke.
HeartSentry targets the rapidly growing selfmeasurement
medical device sector and is designed
for both personal and clinical use. Simplicity and
functionality are key elements of the design.
Designed to efficiently measure increases in arterial
volume which occur when the endothelial cells of the
artery are stimulated, and the muscles in the wall of
the artery relax. Initial studies demonstrated a strong
correlation to ultrasound results.
LXGTF SOLUTION: EARLY DETECTION
The only way to detect that arteries are vulnerable to
atherosclerosis is to assess endothelial function. This is a
test of the endothelial cells that line all the arteries in the body.
The endothelium is the single layer of cells that line various
organs and cavities, especially the heart, blood and lymphatic
vessels. These cells act as a shield, preventing plaque from
forming inside the artery wall, and produce substances that
stop blood clots from developing in the vessel.
Healthy endothelial cells release nitric oxide (NO), which
is responsible for most of the protective functions of these
cells in the artery.
In an at-risk individual, the endothelial cells do not
produce enough NO, or the NO produced is deactivated
by chemicals in the bloodstream before it can prevent
deposits from forming in the arterial wall.